p.82 抽出テキスト

in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertension 2017;35:922–944. https://doi.org/ 10.1097/HJH.0000000000001276 203. Ilkun OL, Greene T, Cheung AK, Whelton PK, Wei G, Boucher RE, et al. The influence of baseline diastolic blood pressure on the effects of intensive blood pressure lowering on cardiovascular outcomes and all-cause mortality in type 2 diabetes. Diabetes Care 2020;43:1878–1884. https://doi.org/10.2337/dc19-2047 204. Blood Pressure Lowering Treatment Trialists’ Collaboration. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet 2021;398:1053–1064. https://doi.org/10.1016/S0140- 6736(21)01921-8 205. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001;344:3–10. https://doi.org/10.1056/ NEJM200101043440101 206. Kastorini C-M, Milionis HJ, Esposito K, Giugliano D, Goudevenos JA, Panagiotakos DB. The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals. J Am College Cardiol 2011;57: 1299–1313. https://doi.org/10.1016/j.jacc.2010.09.073 207. Toledo E, Hu FB, Estruch R, Buil-Cosiales P, Corella D, Salas-Salvadó J, et al. Effect of the Mediterranean diet on blood pressure in the PREDIMED trial: results from a randomized controlled trial. BMC Med 2013;11:207. https://doi.org/10.1186/1741-7015- 11-207 208. Hansen D, Niebauer J, Cornelissen V, Barna O, Neunhäuserer D, Stettler C, et al. Exercise prescription in patients with different combinations of cardiovascular disease risk factors: a consensus statement from the EXPERT Working Group. Sports Med 2018;48:1781–1797. https://doi.org/10.1007/s40279-018-0930-4 209. Beamish AJ, Olbers T, Kelly AS, Inge TH. Cardiovascular effects of bariatric surgery. Nat Rev Cardiol 2016;13:730–743. https://doi.org/10.1038/nrcardio.2016.162 210. Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 2011;34:1481–1486. https://doi.org/ 10.2337/dc10-2415 211. Allhat Officers and Coordinators for the Allhat Collaborative Research Group, The Antihypertensive Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981–2997. https://doi.org/10.1001/jama.288.23.2981 212. Wright JT, Harris-Haywood S, Pressel S, Barzilay J, Baimbridge C, Bareis CJ, et al. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2008;168:207–217. https://doi.org/10.1001/ archinternmed.2007.66 213. Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004–1010. https://doi.org/10.1016/S0140- 6736(02)08090-X 214. Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A; CAPPP Study Group. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/β-blocker–based treatment regimen: a subanalysis of the Captopril Prevention Project. Diabetes Care 2001;24: 2091–2096. https://doi.org/10.2337/diacare.24.12.2091 215. Östergren J, Poulter NR, Sever PS, Dahlöf B, Wedel H, Beevers G, et al. The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. J Hypertension 2008;26:2103–2111. https://doi.org/ 10.1097/HJH.0b013e328310e0d9 216. Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, et al. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am College Cardiol 2010;56:77–85. https://doi.org/10.1016/j.jacc.2010.02.046 217. Kunimura A, Himuro N, Fujiyoshi A, Segawa H, Ohnishi H, Saitoh S. The effects of renin–angiotensin system inhibitors on mortality, cardiovascular events, and renal events in hypertensive patients with diabetes: a systematic review and meta-analysis of randomized controlled trials. Hypertension Res 2019;42:669–680. https://doi.org/10.1038/ s41440-019-0234-6 218. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009;122:290–300. https://doi.org/10.1016/j.amjmed.2008.09.038 219. Bahiru E, de Cates AN, Farr MR, Jarvis MC, Palla M, Rees K, et al. Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases. Cochrane Database Syst Rev 2017;3:CD009868. https://doi.org/10.1002/14651858.CD009868. pub3 220. Jackson AM, Jhund PS, Anand IS, Düngen H-D, Lam CS, Lefkowitz MP, et al. Sacubitril– valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. Eur Heart J 2021;42:3741–3752. https://doi. org/10.1093/eurheartj/ehab499 221. Wang B, Zhong J, Lin H, Zhao Z, Yan Z, He H, et al. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes Metab 2013;15:737–749. https://doi.org/10.1111/dom.12085 222. Liakos CI, Papadopoulos DP, Sanidas EA, Markou MI, Hatziagelaki EE, Grassos CA, et al. Blood pressure-lowering effect of newer antihyperglycemic agents (SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors). Am J Cardiovasc Drugs 2021;21: 123–137. https://doi.org/10.1007/s40256-020-00423-z 223. Mazidi M, Rezaie P, Gao HK, Kengne AP. Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients. J Am Heart Assoc 2017;6:e004007. https://doi.org/10.1161/JAHA.116.004007 224. Ye N, Jardine MJ, Oshima M, Hockham C, Heerspink HJ, Agarwal R, et al. Blood pressure effects of canagliflozin and clinical outcomes in type 2 diabetes and chronic kidney disease: insights from the CREDENCE trial. Circulation 2021;143:1735–1749. https:// doi.org/10.1161/CIRCULATIONAHA.120.048740 225. Kario K, Okada K, Kato M, Nishizawa M, Yoshida T, Asano T, et al. 24-hour blood pressure-lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized, placebo-controlled SACRA study. Circulation 2019;139:2089–2097. https://doi.org/10.1161/ CIRCULATIONAHA.118.037076 226. Georgianos PI, Agarwal R. Ambulatory blood pressure reduction with SGLT-2 inhibitors: dose-response meta-analysis and comparative evaluation with low-dose hydrochlorothiazide. Diabetes Care 2019;42:693–700. https://doi.org/10.2337/dc18-2207 227. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cifkova R, De Bonis M, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy: the task force for the management of cardiovascular diseases during pregnancy of the European Society of Cardiology (ESC). Eur Heart J 2018;39: 3165–3241. https://doi.org/10.1093/eurheartj/ehy340 228. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension 2018;72:24–43. https://doi. org/10.1161/HYPERTENSIONAHA.117.10803 229. Tita AT, Szychowski JM, Boggess K, Dugoff L, Sibai B, Lawrence K, et al. Treatment for mild chronic hypertension during pregnancy. N Engl J Med 2022;386:1781–1792. https://doi.org/10.1056/NEJMoa2201295 230. Wright AK, Welsh P, Gill JM, Kontopantelis E, Emsley R, Buchan I, et al. Age-, sex-and ethnicity-related differences in body weight, blood pressure, HbA1c and lipid levels at the diagnosis of type 2 diabetes relative to people without diabetes. Diabetologia 2020; 63:1542–1553. https://doi.org/10.1007/s00125-020-05169-6 231. Gerdts E, Sudano I, Brouwers S, Borghi C, Bruno RM, Ceconi C, et al. Sex differences in arterial hypertension: a scientific statement from the ESC Council on Hypertension, the European Association of Preventive Cardiology, Association of Cardiovascular Nursing and Allied Professions, the ESC Council for Cardiology Practice, and the ESC Working Group on Cardiovascular Pharmacotherapy. Eur Heart J 2022;43: 4777–4788. https://doi.org/10.1093/eurheartj/ehac470 232. Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013;310:959–968. https://doi.org/10.1001/ jama.2013.184182 233. Lindholt JS, Søgaard R. Population screening and intervention for vascular disease in Danish men (VIVA): a randomised controlled trial. Lancet 2017;390:2256–2265. https://doi.org/10.1016/S0140-6736(17)32250-X 234. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels–updated overview and meta-analyses of randomized trials. J Hypertension 2016;34:613–622. https://doi.org/ 10.1097/HJH.0000000000000881 235. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. J Hypertension 2014;32:2285–2295. https://doi.org/10. 1097/HJH.0000000000000378 236. Zoungas S, Chalmers J, Neal B, Billot L, Li Q, Hirakawa Y, et al. Follow-up of bloodpressure lowering and glucose control in type 2 diabetes. N Engl J Med 2014;371: 1392–1406. https://doi.org/10.1056/NEJMoa1407963 237. McBrien K, Rabi DM, Campbell N, Barnieh L, Clement F, Hemmelgarn BR, et al. Intensive and standard blood pressure targets in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 2012;172:1296–1303. https://doi. org/10.1001/archinternmed.2012.3147 238. Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 2016;387:435–443. https://doi.org/10.1016/S0140-6736(15) 00805-3 Downloaded from academic.oup.com/eurheartj/article/44/39/4043/7238227 by guest on 07 October 2026